000513 Stock Overview Researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Livzon Pharmaceutical Group Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Livzon Pharmaceutical Group Historical stock prices Current Share Price CN¥37.78 52 Week High CN¥44.72 52 Week Low CN¥32.70 Beta 0.24 1 Month Change 2.61% 3 Month Change 7.45% 1 Year Change 9.41% 3 Year Change -5.19% 5 Year Change 16.03% Change since IPO 3,720.04%
Recent News & Updates
Livzon Pharmaceutical Group Inc. Announces Election of Lin Nanqi as Non-Executive Director Nov 29
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Oct 24
Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives the Approval Notice for Supplementary Application for Drug Oct 17
Livzon Pharmaceutical Group Inc. Announces Resignation of Yu Xiong as Director Oct 14
Livzon Pharmaceutical Group Inc. to Report Q3, 2024 Results on Oct 24, 2024 Sep 30
Investor sentiment improves as stock rises 16% Sep 30 See more updates
Livzon Pharmaceutical Group Inc. Announces Election of Lin Nanqi as Non-Executive Director Nov 29
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Oct 24
Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives the Approval Notice for Supplementary Application for Drug Oct 17
Livzon Pharmaceutical Group Inc. Announces Resignation of Yu Xiong as Director Oct 14
Livzon Pharmaceutical Group Inc. to Report Q3, 2024 Results on Oct 24, 2024 Sep 30
Investor sentiment improves as stock rises 16% Sep 30
We Think You Can Look Beyond Livzon Pharmaceutical Group's (SZSE:000513) Lackluster Earnings Aug 30
Livzon Pharmaceutical Group Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next Aug 26
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 23
Now 21% undervalued after recent price drop Aug 21
A Look At The Fair Value Of Livzon Pharmaceutical Group Inc. (SZSE:000513) Aug 09
Now 21% undervalued after recent price drop Aug 01
Livzon Pharmaceutical Group (SZSE:000513) Is Paying Out Less In Dividends Than Last Year Jul 02
Dividend reduced to CN¥1.35 Jul 01
Livzon Pharmaceutical Group Inc. to Report First Half, 2024 Results on Aug 23, 2024 Jun 29
We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right Jun 07 Livzon Pharmaceutical Group Inc., Annual General Meeting, Jun 14, 2024 May 15
Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection Apr 28
Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year Apr 26
Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet? Apr 21
Livzon Pharmaceutical Group Inc. to Report Q1, 2024 Results on Apr 24, 2024 Mar 30
Full year 2023 earnings: Revenues miss analyst expectations Mar 29
Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024 Mar 28
Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist? Mar 15
Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2023 Results on Mar 29, 2024 Dec 29
Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use Dec 05
Livzon Pharmaceutical Group Inc. (SZSE:000513) announces an Equity Buyback for CNY 600 million worth of its shares. Nov 01
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Oct 25
Livzon Pharmaceutical Group Inc. and Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives Acceptance of the Application for the Registration and Marketing Authorization of Triptorelin Acetate Microspheres for Injection Aug 25
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 24
Livzon Pharmaceutical Group Inc. Announces Board Appointments Jul 01 Livzon Pharmaceutical Group Inc. Announces the Final Cash Dividend (A Shares) (Tax Included) for 2022, Payable on 04 July 2023
Livzon Pharmaceutical Group Inc. Approves Final Cash Dividend for the Year Ended 31 December 2022, Payable on 31 July 2023 Jun 22
Full year 2022 earnings: Revenues in line with analyst expectations Apr 01
Livzon Pharmaceutical Group Inc. Announces Approval of Drug Marketing Authorisation Submitted by Livzon MABPharm Inc. for the Tocilizumab Injection Atvtia Jan 20
Now 20% undervalued Dec 27
Less than half of directors are independent Nov 16
Third quarter 2022 earnings: Revenues miss analyst expectations Oct 26
Livzon Pharmaceutical Group Inc. to Report Nine Months, 2022 Results on Oct 25, 2022 Sep 29
Price target decreased to CN¥42.19 Aug 11
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 11
Livzon Pharmaceutical Group Inc. Receives Approval Notice for Supplementary Application for Drug Jul 28
Livzon Pharmaceutical Group Inc. to Report First Half, 2022 Results on Aug 09, 2022 Jul 19 Livzon Pharmaceutical Announces on Drug Passing Consistency Evaluation for Generics Jun 03
Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2021 May 24
Less than half of directors are independent Apr 27
Livzon Pharmaceutical Group Inc., Annual General Meeting, May 20, 2022 Apr 13
Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on June 24, 2022 Apr 12
Livzon Pharmaceutical Group Inc. to Report Q1, 2022 Results on Apr 21, 2022 Apr 07
Full year 2021 earnings: EPS misses analyst expectations Mar 30
Livzon Pharmaceutical Group Inc. Announces Ordinary Final Dividend for the Year Ended December 31, 2021, Payable on June 24, 2022 Mar 29
Investor sentiment improved over the past week Mar 22
Livzon Pharmaceutical Group Inc. Obtains Approval Notice for Clinical Trial on Drug from National Medical Products Administration Feb 25
Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.44 in 3Q 2020) Oct 26
Non-Executive Vice Chairman exercised options to buy CN¥239k worth of stock. Sep 18
Livzon Pharmaceutical Group Inc. Announces Approval Notice for Clinical Trial on A Drug Sep 12
Non-Executive Vice Chairman exercised options to buy CN¥408k worth of stock. Sep 08
Second quarter 2021 earnings released: EPS CN¥0.58 (vs CN¥0.64 in 2Q 2020) Aug 26
Independent Non-Executive Director Zhihua Zheng has left the company Aug 04
Independent Non-Executive Director Yun Xie has left the company Aug 04
Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2020, Payable on or Before June 25, 2021 May 21
Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of share transfer agreement to acquire a 40% stake in Tianjin Tongrentang Group Co., Ltd. from Tianjin Tasly Healthcare Industry Investment Partnership. Apr 28
New 90-day low: CN¥34.73 Mar 10
Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021 Feb 20
Investor sentiment deteriorated over the past week Jan 29
New 90-day low: CN¥38.49 Jan 26
Livzon Pharmaceutical Group Inc. announced that it expects to receive CNY 961.6 million in funding from YF Pharmab Limited Jan 20
New 90-day low: CN¥42.15 Dec 23
President & Executive Director exercised options to buy CN¥2.7m worth of stock. Nov 14
New 90-day low: CN¥46.34 Nov 06
Third quarter earnings released Oct 25
Third-quarter earnings released: Revenue and earnings beat expectations Oct 25
Livzon Pharmaceutical Group Inc. to Report Nine Months, 2020 Results on Oct 23, 2020 Oct 13
Price target raised to CN¥51.22 Sep 02
Earnings released Aug 26
Livzon Pharmaceutical Group Inc. to Report First Half, 2020 Results on Aug 26, 2020 Aug 06
New 90-day high - CN¥56.12 Aug 03 Shareholder Returns 000513 CN Pharmaceuticals CN Market 7D -0.7% -1.9% -1.2% 1Y 9.4% -1.8% 11.8%
See full shareholder returns
Return vs Market: 000513 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility Is 000513's price volatile compared to industry and market? 000513 volatility 000513 Average Weekly Movement 4.1% Pharmaceuticals Industry Average Movement 7.4% Market Average Movement 8.7% 10% most volatile stocks in CN Market 12.8% 10% least volatile stocks in CN Market 5.7%
Stable Share Price: 000513 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 000513's weekly volatility (4%) has been stable over the past year.
About the Company Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precocious puberty; and Urofollitropin for injection to treat anovulation and sufferers. It also provides Perospirone hydrochloride tablets to treat schizophrenia; Shenqi Fuzheng Injection to treat weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for treating lung and stomach cancer; anti-viral granules used for clearing heat, eliminating dampness, cooling blood, and detoxifying to treat upper respiratory tract infection and influenza; Tocilizumab injection to treat rheumatoid arthritis; and Recombinant SARSCoV-2 fusion protein vaccine used to prevent diseases caused by SARS-CoV-2 infection.
Show more Livzon Pharmaceutical Group Inc. Fundamentals Summary How do Livzon Pharmaceutical Group's earnings and revenue compare to its market cap? 000513 fundamental statistics Market cap CN¥30.43b Earnings (TTM ) CN¥2.02b Revenue (TTM ) CN¥11.86b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 000513 income statement (TTM ) Revenue CN¥11.86b Cost of Revenue CN¥4.39b Gross Profit CN¥7.46b Other Expenses CN¥5.44b Earnings CN¥2.02b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 2.23 Gross Margin 62.94% Net Profit Margin 17.08% Debt/Equity Ratio 27.4%
How did 000513 perform over the long term?
See historical performance and comparison Dividends
3.6% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 06:04 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Livzon Pharmaceutical Group Inc. is covered by 30 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ling Zhang BNP Paribas Securities (Asia) Helena Qiu CCB International Securities Limited Shuchang Liu Changjiang Securities Co. LTD.
Show 27 more analysts 
